Please login to your online account to display your discounted pricing

Epidermal Growth Factor Receptor-2 (ErbB2/HER-2) Mouse anti-Human, Clone: MJD2, eBioscience™

Mouse Monoclonal Antibody

$158.05 - $390.05

Specifications

Antigen Epidermal Growth Factor Receptor-2 (ErbB2/HER-2)
Clone MJD2
Host Species Mouse
Gene Alias HER2
Species Reactivity Human
View More Specs

 Disclaimers

For Research Use Only.

Products
Catalog Number Mfr. No. Quantity Price Quantity    

501122827

 
affymetrix
14975780
25μg Each for $158.05

501122828

 
affymetrix
14975782
100μg Each for $390.05
Description & Specifications

Specifications

Antigen Epidermal Growth Factor Receptor-2 (ErbB2/HER-2)
Clone MJD2
Host Species Mouse
Gene Alias HER2
Species Reactivity Human
Applications Immunocytochemistry
Applications Immunohistochemistry (Formalin/Paraffin)
Applications Microscopy
Applications Western Blotting
Regulatory Status RUO
Conjugate Unlabeled
Format Purified
Storage Requirements Store at 2-8°C.
Primary or Secondary Primary
Monoclonal or Polyclonal Monoclonal
Formulation aqueous buffer, 0.09% sodium azide, may contain carrier protein/stabilizer
Concentration 0.5mg/mL

This MJD2 monoclonal antibody reacts with HER-2, the product of the ErbB2 gene and a member of the human epidermal growth factor receptor (EGFR) family. HER-2 is a 185kDa transmembrane receptor with an extracellular binding domain and an intracellular tyrosine kinase domain. Activation of HER-2 occurs following formation of homodimers or heterodimers with ligand-bound EGFR family members, HER3 or HER4. Overexpression of HER-2 results in auto-phosphorylation and increased proliferation and invasiveness and is associated with subsets of multiple cancer types such as breast, ovarian, cervical, uterine, and gastric. The use of HER-2 targeted agents has been used extensively to treat HER-2-positive breast cancer, but a recent study found that these agents can also block the proliferation of breast cancer stem cells found in HER-2-negative patients and suggests the importance of HER-2 as a target for multiple types of breast cancer. The MJD2 antibody recognizes the extracellular domain of HER-2 but at an epitope distinct from that recognized by the 4D5 (Herceptin) and SP3 monoclonal antibodies.